Search Medical Condition
Please enter condition
Please choose location from dropdown

Barrington, Illinois Clinical Trials

A listing of Barrington, Illinois clinical trials actively recruiting patient volunteers.

RESULTS

Found (67) clinical trials

Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults

The purpose of this is study is to compare the efficacy of BHV-3000 (rimegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.

Phase

7.07 miles

Learn More »

Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia Schizophreniform or Bipolar I Disorder

In the US adolescent subjects starting at age 16 will be enrolled. In the EU, subjects age 18 and older will be enrolled.

Phase

7.26 miles

Learn More »

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

To evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of adjunctive treatment in subjects with schizophrenia

Phase

7.26 miles

Learn More »

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder

A multicenter, randomized, double-blind trial of Brexpiprazole versus Placebo for the acute treatment of manic episodes, with or without mixed features, associated with bipolar I disorder. This study will also demonstrate the safety and tolerability of brexpiprazole in the study population of males and females aged 18 to 65 years ...

Phase

7.26 miles

Learn More »

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

The main purpose of this study is to determine the safety and efficacy of the study drug galcanezumab in participants 6 to 17 years of age with episodic migraine.

Phase

7.26 miles

Learn More »

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients

This study will consist of 4 study periods of up to 50 months in total, consisting of: Screening Period - A maximum screening duration of 4 weeks. Treatment Period - Treatment Arm A up to 24 months; Treatment Arm B up to 12 months. End of Treatment Visit - A ...

Phase

7.73 miles

Learn More »

A Long-term Safety Study of Intranasal Esketamine in Treatment-resistant Depression

This is an open-label (the researchers and participants know the treatment the participant is receiving) long-term extension study. The study will consist of 2 open-label Phases: 4-week Induction phase (if applicable) and Open-Label Optimization/Maintenance phase (variable). Participants will enter the study Induction Phase from ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585), ESKETINTRD3003 (NCT02493868), ...

Phase

7.92 miles

Learn More »

Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Patients With Bipolar I Disorder

This study is designed to prospectively confirm the efficacy of a fixed-dose regimen of cariprazine 1.5 mg/day or 3 mg/day compared to placebo for treatment of the depressive episode in patients with bipolar I disorder. The safety and tolerability of the fixed-dose regimens will be evaluated.

Phase

7.92 miles

Learn More »

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.

Phase

7.92 miles

Learn More »

Lacripep in Subjects With Dry Eye Associated With Primary Sj gren's Syndrome

This is a multi-center, randomized, placebo-controlled, double-masked, parallel-group study. Subjects will be randomized into three treatment groups: 0.005%, or 0.01% Lacripep, or placebo in a 1:1:1 ratio.

Phase

7.92 miles

Learn More »